Biopharmaceutical News and Research

RSS

Nikalyte Announces New Partnership with Life Science Group Calibre Scientific

Nanoparticle deposition specialists, Nikalyte Ltd announced that the company has signed a partnership agreement with global life sciences group Calibre Scientific.

From Nikalyte Ltd 8 Jul 2021

WEHI collaborates with Boehringer Ingelheim to develop novel anti-cancer therapeutics

WEHI has partnered with Boehringer Ingelheim, a leading research-driven pharmaceutical company, in a collaboration to discover and develop anti-cancer therapeutics using a promising new technology called targeted protein degradation.

25 Jun 2021

Repligen Corporation Announces Agreement to Acquire Polymem S.A.

Repligen Corporation today announced that it has entered into an agreement to acquire Toulouse, France-based Polymem S.A., a leading industrial expert.

23 Jun 2021

Insilico Medicine receives $255 million to develop AI and drug discovery capabilities

Insilico Medicine, a global leader in end-to-end artificial intelligence for target discovery, small molecule chemistry, and clinical development, announced that it has closed a $255 million from biotechnology experts to progress Insilico Medicine's current therapeutic programs into human clinical trials, initiate multiple new programs for novel and difficult targets, and further develop its AI and drug discovery capabilities.

23 Jun 2021

Study determines the mechanism behind respiratory inflammation and finds effective treatment

Applied Biological Laboratories (Applied Bio), a biopharmaceutical company focused on the respiratory disease market, announced that its study published online in Immunology, Inflammation and Disease was able to determine the mechanism behind respiratory inflammation and treat it effectively with Biovanta(TM), a 100% naturally derived, over-the-counter (OTC) drug for cold, cough and sore throat.

22 Jun 2021

RedHill presents positive Phase 2 results for oral opaganib in patients with COVID-19 pneumonia

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced presentation of the positive Phase 2 safety and efficacy data for oral opaganib (Yeliva®, ABC294640) in hospitalized patients with COVID-19 pneumonia at the World Microbe Forum (WMF) 2021 (poster #: 5574).

21 Jun 2021

KIYATEC’s test results accurately predict treatment response in recurrent high-grade glioma patients

KIYATEC, Inc. announced today the publication of new peer-reviewed data that establishes clinically meaningful prediction of patient-specific responses to standard of care therapy, prior to treatment, in newly diagnosed glioblastoma (GBM) and other high-grade glioma (HGG) patients.

18 Jun 2021

Foresight Diagnostics to demonstrate utility of PhasED-Seq technology at ICML meeting

Foresight Diagnostics, the emerging leader in blood-based lymphoma disease monitoring, announced today that clinical performance of its minimal residual disease (MRD) detection platform in diffuse large B-cell lymphoma (DLBCL) will be presented at the 16th International Conference on Malignant Lymphoma (ICML) on June 18-22, 2021.

18 Jun 2021

Enterprise Therapeutics doses first subjects in Phase I trial for novel cystic fibrosis therapy ETD001

Enterprise Therapeutics Ltd today announced it has successfully dosed the first subjects in a Phase 1 trial for its novel inhaled cystic fibrosis therapy, ETD001.

14 Jun 2021

PhoreMost appoints Christian Dillon as Vice President of Biology

PhoreMost Ltd today announced it has appointed Dr Christian Dillon as Vice President of Biology.

From PhoreMost 14 Jun 2021

Autobahn Labs collaborates with CSHL to advance science from the lab to clinic

Autobahn Labs, an early-stage drug discovery incubator, today announced a new strategic venture collaboration with Cold Spring Harbor Laboratory.

7 Jun 2021

Redhill Biopharma announces completion of enrollment for oral opaganib phase 2/3 COVID-19 study

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced that it has completed enrollment and randomized the last patient in the global Phase 2/3 study with opaganib (Yeliva, ABC294640) in patients hospitalized with severe COVID-19 pneumonia (NCT04467840).

7 Jun 2021

Scientists test antibody-based therapy to treat Crimean-Congo hemorrhagic fever virus

Army scientists working as part of an international consortium have developed and tested an antibody-based therapy to treat Crimean-Congo hemorrhagic fever virus (CCHFV), which is carried by ticks and kills up to 60 percent of those infected.

2 Jun 2021

Aptamer Group collaborates with world-leading pharmaceutical company to evaluate Optimer technology

Aptamer Group today announced that it has signed an agreement with the multinational pharmaceutical and biopharmaceutical company Takeda.

From Aptamer Group 28 May 2021

New tool will help identify the most promising protein molecules for drug development

A cutting-edge digital tool that will make it cheaper, safer and faster for pharmaceutical companies to predict protein stability - a vital step in the development of new medicines - is being rolled out by scientists from the UK's University of Bath through their spin-out company, BLOC Labs.

28 May 2021

Adaptimmune to report Phase 2 trial data on synovial sarcoma at ASCO congress

Adaptimmune Therapeutics plc, a leader in cell therapy to treat cancer, will report initial data from its Phase 2 SPEARHEAD-1 trial, with afamitresgene autoleucel (afami-cel, formerly ADP-A2M4), at the American Society of Clinical Oncology (ASCO) congress. Full abstracts were released online today.

21 May 2021

Farxiga approved in the US for the treatment of chronic kidney disease in patients at risk of progression with and without type-2 diabetes

Approval is the most significant advancement in the treatment of chronic kidney disease in more than 20 years. In DAPA-CKD Phase III trial, Farxiga demonstrated unprecedented reduction in the risk of the composite of worsening of renal function, end-stage kidney disease and cardiovascular or renal death.

From AstraZeneca 14 May 2021

ProductLife Group Enters US Market with Acquisition of Leading Regulatory Drug Development Consultancy DS InPharmatics (DSI)

ProductLife Group (PLG) has taken the next step in its evolution as a global leader in end-to-end regulatory compliance services.

From DSI, a PLG Company 30 Apr 2021

Topical therapy can help safely reduce side effect of cancer treatment

Patients with advanced colorectal cancer may be spared from a toxic side effect caused by a type of targeted therapy used to treat the cancer with the help of another drug normally used to treat melanoma, according to a study led by researchers at the UCLA Jonsson Comprehensive Cancer Center and Memorial Sloan Kettering Cancer Center.

28 Apr 2021

Albumedix extends research collaboration with Cobra Biologics to optimize viral vector manufacturing

Albumedix Ltd. ('Albumedix'), an emerging leader in the enablement of advanced therapies and recognized global leader in recombinant human albumin (rHA) has today announced an extension to its research collaboration with Cobra Biologics, the gene therapy division of Cognate BioServices, a Charles River Laboratories International, Inc. company.

From Albumedix Ltd. 28 Apr 2021